Abstract
The RAS/RAF/MEK/ ERK and the PI3K/AKT/mTOR pathways govern fundamental physiological processes, such as cell proliferation, differentiation, metabolism, cytoskeleton reorganization and cell death and survival. Constitutive activation of these signal transduction pathways is a required hallmark of cancer and dysregulation, on either genetic or epigenetic grounds, of these pathways has been implicated in the initiation, progression and metastastic spread of lung cances. Targeting components of the MAPK and PI3K cascades is thus an attractive strategy in the development of novel therapeutic approaches to treat lung cancer, although the use of single pathway inhibitors has met with limited clinical success so far. Indeed, the presence of intra- and inter-pathway compensatory loops that re-activate the very same cascade, either upstream or downstream the point of pharmacological blockade, or activate the alternate pathway following the blockade of one signaling cascade has been demonstrated, potentially driving preclinical (and possibly clinical) resistance. Therefore, the blockade of both pathways with combinations of signaling inhibitors might result in a more efficient anti-tumor effect, and thus potentially overcome and/or delay clinical resistance, as compared with single agent. The current review aims at summarizing the current status of preclinical and clinical research with regard to pathway crosstalks between the MAPK and PI3K cascades in NSCLC and the rationale for combined therapeutic pathway targeting.
Keywords: MAPK, PI3K, NSCLC, Crosstalk, Feedback loops, Combination therapy.
Current Pharmaceutical Design
Title:Signaling Intermediates (MAPK and PI3K) as Therapeutic Targets in NSCLC
Volume: 20 Issue: 24
Author(s): Ludovica Ciuffreda, Ursula Cesta Incani, Linda S. Steelman, Stephen L. Abrams, Italia Falcone, Anais Del Curatolo, William H. Chappell, Richard A. Franklin, Sabrina Vari, Francesco Cognetti, James A. McCubrey and Michele Milella
Affiliation:
Keywords: MAPK, PI3K, NSCLC, Crosstalk, Feedback loops, Combination therapy.
Abstract: The RAS/RAF/MEK/ ERK and the PI3K/AKT/mTOR pathways govern fundamental physiological processes, such as cell proliferation, differentiation, metabolism, cytoskeleton reorganization and cell death and survival. Constitutive activation of these signal transduction pathways is a required hallmark of cancer and dysregulation, on either genetic or epigenetic grounds, of these pathways has been implicated in the initiation, progression and metastastic spread of lung cances. Targeting components of the MAPK and PI3K cascades is thus an attractive strategy in the development of novel therapeutic approaches to treat lung cancer, although the use of single pathway inhibitors has met with limited clinical success so far. Indeed, the presence of intra- and inter-pathway compensatory loops that re-activate the very same cascade, either upstream or downstream the point of pharmacological blockade, or activate the alternate pathway following the blockade of one signaling cascade has been demonstrated, potentially driving preclinical (and possibly clinical) resistance. Therefore, the blockade of both pathways with combinations of signaling inhibitors might result in a more efficient anti-tumor effect, and thus potentially overcome and/or delay clinical resistance, as compared with single agent. The current review aims at summarizing the current status of preclinical and clinical research with regard to pathway crosstalks between the MAPK and PI3K cascades in NSCLC and the rationale for combined therapeutic pathway targeting.
Export Options
About this article
Cite this article as:
Ciuffreda Ludovica, Incani Cesta Ursula, Steelman S. Linda, Abrams L. Stephen, Falcone Italia, Curatolo Del Anais, Chappell H. William, Franklin A. Richard, Vari Sabrina, Cognetti Francesco, McCubrey A. James and Milella Michele, Signaling Intermediates (MAPK and PI3K) as Therapeutic Targets in NSCLC, Current Pharmaceutical Design 2014; 20 (24) . https://dx.doi.org/10.2174/13816128113196660763
DOI https://dx.doi.org/10.2174/13816128113196660763 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
Advances in the Molecular Pathogenesis of Inflammatory Bowel Disease.
This thematic issue will emphasize the recent breakthroughs in the mechanisms of Inflammatory bowel disease (IBD) pathogenesis and devotes some understanding of both Crohn’s and ulcerative colitis. It is expected to include studies about cellular and genetic aspects, which help to precipitate the disease, and the immune system-gut microbiome relations ...read more
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employed in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, and prediction, to monitoring of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Role of Survivin for Radiation Oncology: Moving Beyond Apoptosis Inhibition
Current Medicinal Chemistry 3,5-Bis(trifluoromethyl) Phenylammonium triflate(BFPAT) as a Novel Organocatalyst for the Efficient Synthesis of 2,3-dihydroquinazolin-4(1H)-one Derivatives
Current Organic Synthesis Palladium (II) Complex Enhances ROS-Dependent Apoptotic Effects <i>via</i> Autophagy Inhibition and Disruption of Multiple Signaling Pathways in Colorectal Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Old Drugs-Current Perspectives
Current Pharmacogenomics Advances in the Chemistry and Pharmacology of Ecteinascidins, A Promising New Class of Anticancer Agents
Current Medicinal Chemistry - Anti-Cancer Agents Genomics of Addiction
Current Psychiatry Reviews Targeting Mitochondria in Fighting Cancer
Current Pharmaceutical Design ANN-QSAR Model for Virtual Screening of Androstenedione C-Skeleton Containing Phytomolecules and Analogues for Cytotoxic Activity Against Human Breast Cancer Cell Line MCF-7
Combinatorial Chemistry & High Throughput Screening Mannich Base Derivatives as the Potential Candidates of Human Topoisomerase II Inhibitors
Letters in Drug Design & Discovery SANTAVAC ™: A Novel Universal Antigen Composition for Developing Cancer Vaccines
Recent Patents on Biotechnology The Stem Cell Factor Receptor/c-Kit as a Drug Target in Cancer
Current Cancer Drug Targets Adaptors in Toll-Like Receptor Signaling and their Potential as Therapeutic Targets
Current Drug Targets Herpes Simplex Virus Type 1 Amplicons and their Hybrid Virus Partners, EBV, AAV, and Retrovirus
Current Gene Therapy Policy and Adolescent Tobacco Use Prevention
Adolescent Psychiatry Chemopreventive Properties and Molecular Mechanisms of the Bioactive Compounds in Hibiscus Sabdariffa Linne
Current Medicinal Chemistry Therapeutic Potential of Perineural Invasion, Hypoxia and Desmoplasia in Pancreatic Cancer
Current Pharmaceutical Design Editorial: The Real Impact of Target Therapy in Cancer Patients: Between Hope and Reality
Current Cancer Drug Targets Therapeutic Nanoparticles and Associated Toxicity
Current Nanoscience Bovine Serum Albumin as a Versatile Platform for Cancer Imaging and Therapy
Current Medicinal Chemistry Role of Thymidine Phosphorylase in Biomodulation of Fluoropyrimidines
Current Pharmaceutical Biotechnology